1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. PMID:
20610543.
2. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-447. PMID:
2842549.
3. Putila J, Remick SC, Guo NL. Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One 2011;6:e17493PMID:
21364765.
4. Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010;5:1748-1754. PMID:
20881643.
5. Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, et al. Association of the transforming growth factor ss1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer. Oncol Rep 2011;25:377-382. PMID:
21165571.
6. Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, et al. Transforming growth factor-beta1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol 2010;31:437-441. PMID:
20506050.
7. Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, et al. Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population. J Thorac Oncol 2010;5:658-666. PMID:
20234319.
8. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011;6:296-304. PMID:
21206385.
10. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-4161. PMID:
15736466.
11. Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-123. PMID:
8261432.
12. Di Bernardo MC, Matakidou A, Eisen T, Houlston RS. GELCAPS Consortium. Plasminogen activator inhibitor variants
PAI-1 A15T and
PAI-2 S413C influence lung cancer prognosis. Lung Cancer 2009;65:237-241. PMID:
19117638.
13. Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, et al. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling. Exp Cell Res 2006;312:1093-1105. PMID:
16457817.
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957. PMID:
19692680.
15. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. PMID:
9187198.
16. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. PMID:
11829087.
17. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501. PMID:
15710947.
18. Samarakoon R, Higgins CE, Higgins SP, Higgins PJ. TGF-beta1-induced expression of the poor prognosis
SERPINE1/PAI-1 gene requires EGFR signaling: a new target for anti-EGFR therapy. J Oncol 2009;2009:342391PMID:
19365582.
19. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-548. PMID:
15234235.
20. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-643. PMID:
10676647.
22. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997;226:736-744. PMID:
9409572.
23. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. The RANX05 Colorectal Cancer Study Group. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. Ann Surg Oncol 2000;7:617-623. PMID:
11005561.
24. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity: clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-196. PMID:
15878520.
25. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49. PMID:
14754404.
26. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008;214:283-293. PMID:
18095256.
27. Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008;118:116-124. PMID:
18495253.
28. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-4675. PMID:
8062262.
29. Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, et al. Rotterdam Oncology Thoracic Study Group. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Ann Oncol 2000;11:327-332. PMID:
10811500.
30. Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 2007;56:43-50. PMID:
17207889.
31. Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang JY, Kristensen P, Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralization and one-step affinity purification. Thromb Haemost 1986;55:206-212. PMID:
3520936.
32. Bouchard L, Mauriege P, Vohl MC, Bouchard C, Perusse L. Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005;12:136-143. PMID:
15772559.
33. French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, et al. A
PAI-1 (
SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:4496-4499. PMID:
18285546.
34. Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics 2008;18:869-875. PMID:
18794724.
35. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005;112:1728-1735. PMID:
16172282.